StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
SYNT.ST$0.82-2.38%
Fair $0.82+0.0%

SYNT.ST

SYNT.ST

Healthcare / Health Information ServicesStockholm

$0.82

-0.02 (-2.38%)

Fairly Valued+0.0%Fair Value $0.82Fund rank 23/100 · Data gapFallback financials|
SA 8/F
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $-13.4M · quality 51.7/100

Data gap 23/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 28/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

8/100

F

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -51.8%, below the 5% threshold
Thesis & Journal · SYNT.STLocal privado en este navegador · SYNT.ST
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$73M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-51.8%

↓

Gross Margin

112.3%

↑

Debt/Equity

N/A

•
52-Week Range$1
$1$4

TradingView lightweight chart

SYNT.ST price, volumen y niveles de valoración

Último $0.820Periodo -59.2%
Fair value: $0.820

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-5.8%

FCF CAGR

—

FCF margin

-23.5%

FCF / Net income

0.24x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $57.0M · net income $-54.9M · FCF $-13.4M

2022-FY → 2025-FY

Gross margin

112.3%+4.5% pts

Operating margin

-87.7%-94.7% pts

Net margin

-96.3%-104.9% pts

FCF margin

-23.5%+14.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$57.0M$57.0M$55.7M$89.2M$68.3M
Net Income$-54.9M$-54.9M$-16.1M$10.0M$5.9M
EBITDA$-42.7M$-42.7M$-8.9M$19.4M$13.1M
EPS-0.90-0.90-0.360.210.13
Gross Margin112.3%112.3%110.8%105.8%107.8%
Operating Margin-87.7%-87.7%-35.3%15.8%7.0%
Net Margin-96.3%-96.3%-28.9%11.2%8.6%
Balance Sheet
Debt/Equity——0.030.010.02
Current Ratio3.043.04———
Cash Flow
Free Cash Flow$-13.4M$-13.4M$-10.4M$-16.7M$-25.7M
Returns
ROE-51.8%-51.8%-15.9%8.6%5.5%
Valuation
P/E———125.02270.65
EV/EBITDA———60.78124.80
P/B0.490.491.9810.2715.66
Growth & Yield
Revenue Growth2.5%2.5%-37.6%30.7%—
EPS Growth-148.7%-148.7%-269.6%62.8%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -72.3%

Total return

-72.3%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.36 → -0.90

Residual

-72.3%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-72.3%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.